171 related articles for article (PubMed ID: 1368788)
1. Controlling chirality in enzymatic synthesis.
Hodgson J
Biotechnology (N Y); 1992 Oct; 10(10):1093-7. PubMed ID: 1368788
[No Abstract] [Full Text] [Related]
2. Industrial biotransformations in the synthesis of building blocks leading to enantiopure drugs.
Muñoz Solano D; Hoyos P; Hernáiz MJ; Alcántara AR; Sánchez-Montero JM
Bioresour Technol; 2012 Jul; 115():196-207. PubMed ID: 22230779
[TBL] [Abstract][Full Text] [Related]
3. Chirality and its importance in drug development.
Campbell DB; Wilson K
Biochem Soc Trans; 1991 Apr; 19(2):472-5. PubMed ID: 1889635
[No Abstract] [Full Text] [Related]
4. High-throughput and parallel screening methods in asymmetric hydrogenation.
Jäkel C; Paciello R
Chem Rev; 2006 Jul; 106(7):2912-42. PubMed ID: 16836304
[No Abstract] [Full Text] [Related]
5. Trends in the development of chiral drugs.
Caner H; Groner E; Levy L; Agranat I
Drug Discov Today; 2004 Feb; 9(3):105-10. PubMed ID: 15038394
[No Abstract] [Full Text] [Related]
6. Biocatalysis: synthesis of chiral intermediates for drugs.
Patel RN
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):741-64. PubMed ID: 17117684
[TBL] [Abstract][Full Text] [Related]
7. Drug discovery: the leading edge.
Chapman T
Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608
[No Abstract] [Full Text] [Related]
8. Chiral drugs viable, despite failure.
Dorey E
Nat Biotechnol; 2000 Dec; 18(12):1239-40. PubMed ID: 11101795
[No Abstract] [Full Text] [Related]
9. Europe's sweeping chemical law puts medicines in peril.
Keim B
Nat Med; 2007 Jan; 13(1):4. PubMed ID: 17297677
[No Abstract] [Full Text] [Related]
10. Achieving continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Badman C; Trout BL
J Pharm Sci; 2015 Mar; 104(3):779-80. PubMed ID: 25501284
[No Abstract] [Full Text] [Related]
11. Aligning pharmaceutical innovation with medical need.
Nathan C
Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
[No Abstract] [Full Text] [Related]
12. Homochiral drugs: a demanding tendency of the pharmaceutical industry.
Núñez MC; García-Rubiño ME; Conejo-García A; Cruz-López O; Kimatrai M; Gallo MA; Espinosa A; Campos JM
Curr Med Chem; 2009; 16(16):2064-74. PubMed ID: 19519381
[TBL] [Abstract][Full Text] [Related]
13. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
Miller CP; Ullrich JW
Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
[TBL] [Abstract][Full Text] [Related]
14. Chirality and its importance in drug development: an analytical chemist's perspective.
Fell AF; Ley GW
Biochem Soc Trans; 1991 Apr; 19(2):454-6. PubMed ID: 1889628
[No Abstract] [Full Text] [Related]
15. Forewords BMC.
Gallou F
Bioorg Med Chem; 2018 Aug; 26(14):4329. PubMed ID: 29983282
[No Abstract] [Full Text] [Related]
16. The acceptable face of international competition. Stereophobia: an economic afterthought.
Ariëns EJ
Trends Pharmacol Sci; 1988 Sep; 9(9):317. PubMed ID: 3270968
[No Abstract] [Full Text] [Related]
17. From genes to products: innovations in drug discovery.
Afshar M
Drug Discov Today; 2003 May; 8(9):392-4. PubMed ID: 12706655
[No Abstract] [Full Text] [Related]
18. Palladium coupling catalysts for pharmaceutical applications.
Doucet H; Hierso JC
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):672-90. PubMed ID: 17987520
[TBL] [Abstract][Full Text] [Related]
19. Regulatory implications: a company's perspective.
Macdonald CM
Biochem Soc Trans; 1991 Apr; 19(2):467-8. PubMed ID: 1889633
[No Abstract] [Full Text] [Related]
20. A return to the fundamentals of drug discovery?
Williams M
Curr Opin Investig Drugs; 2004 Jan; 5(1):29-33. PubMed ID: 14983970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
